CJC-1295 / Ipamorelin

CJC-1295 / Ipamorelin

CJC-1295 and Ipamorelin are synthetic peptide compounds frequently studied together in laboratory research due to their complementary mechanisms of action within growth hormone regulatory pathways. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. This combination has become a valuable research model for investigating endocrine signaling, receptor interactions, and peptide synergy.

In laboratory and preclinical research, the CJC-1295/Ipamorelin combination has been investigated for its potential roles in:

• Growth hormone signaling pathways
• GHRH receptor activation
• Growth hormone secretagogue receptor (GHSR) signaling
• Endocrine signaling mechanisms
• Insulin-like growth factor (IGF) pathway research
• Cellular growth signaling
• Protein synthesis pathways
• Cellular metabolism
• Mitochondrial function
• Skeletal muscle biology
• Connective tissue physiology
• Bone metabolism
• Cellular regeneration mechanisms
• Energy metabolism
• Circadian rhythm and pulsatile hormone signaling
• Receptor pharmacology
• Signal transduction pathways
• Peptide synergy and multi-receptor interactions
• Cellular adaptation to metabolic stress
• Molecular mechanisms of endocrine regulation

The CJC-1295/Ipamorelin combination continues to serve as an important research tool for investigating the coordinated regulation of growth hormone pathways, receptor pharmacology, and cellular signaling networks. Ongoing studies seek to further characterize its biological activity, receptor interactions, and downstream molecular mechanisms across a variety of experimental models.

Research Use Only (RUO): This product is intended exclusively for laboratory and scientific research. It is not intended for human or veterinary use, diagnosis, treatment, or consumption.